Login to Your Account



Phase III So Far, So Good, but . . .

Amgen's Early Melanoma Data: Analysts 'Overall' in Wait Mode

By Randy Osborne
Staff Writer

Wednesday, March 20, 2013
Amgen Inc.'s $1 billion buyout in 2011 of BioVex Group Inc., which brought aboard the melanoma therapy then known as OncoVex, may be paying off, but analysts are waiting for overall survival (OS) Phase III data before they start jumping up and down about the compound, now called talimogene laherparepvec, or T-VEC.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription